ArticleCureus2025
Biological Agents' Adverse Events in Jordanian Childhood Rheumatic Diseases: A Single-Center Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tocilizumab for Non-Infectious Uveitis: A Systematic Review.Journal of inflammation research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic diseases encompass a heterogeneous group of autoimmune and autoinflammatory disorders affecting joints, muscles, and connective tissue, with juvenile idiopathic arthritis (JIA) being the most prevalent among children. The introduction of biological agents in the treatment of childhood rheumatic diseases has significantly improved outcomes and quality of life. However, there is limited data on the use of biological agents in Jordanian children with these conditions. This study aims to evaluate the clinical indications for initiating biological agents and investigate the safety profile of biological therapy in Jordanian children. This retrospective study was conducted at Queen Rania Children's Hospital, including children (under 14 years of age) diagnosed with rheumatic diseases between January 2019 and December 2023. Data collected and reviewed included demographic characteristics, diagnosis, concomitant use of disease-modifying conventional synthetic antirheumatic drugs (csDMARD), indications for starting biological agents, age at initiation of therapy, and reported side effects during treatment. A total of 177 patients (57.6% females) with various rheumatic disorders were treated with biological therapy. The mean age at diagnosis was 7 years (range: 1-7 years), while the mean age at therapy initiation was 8.6 years (range: 4.2-14 years). JIA was the most common diagnosis in 110 patients (62%), followed by non-infectious uveitis in 18 patients (10.1%) and autoinflammatory disorders in 17 patients (9.6%). Concomitant therapy with DMARDs and corticosteroids was employed in 92.6% of cases (164 patients). A total of 290 biological treatments were administered, including infliximab (93; 32%), etanercept (71; 24.4%), adalimumab (48; 16.5%), tocilizumab (41; 14.1%), and anakinra (13; 4.4%). In 66 patients (37.2%), the biological agent was switched, primarily due to inefficacy (56 patients, 84.7%) or adverse events (10 patients, 15.3%). A total of 64 adverse events (36.1%) were reported, the most common being infections (29; 45.3%), local reactions (11; 17.1%), and infusion-related reactions (10; 15.6%). This retrospective study highlights the importance of evaluating the efficacy and safety of biological agents in treating childhood rheumatic diseases. The findings can help optimize treatment strategies and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.